Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Position Statement

6. Obesity Management for the Treatment of Type 2 Diabetes

  1. American Diabetes Association
Diabetes Care 2016 Jan; 39(Supplement 1): S47-S51. https://doi.org/10.2337/dc16-S009
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

There is strong and consistent evidence that obesity management can delay progression from prediabetes to type 2 diabetes (1,2) and may be beneficial in the treatment of type 2 diabetes. In overweight and obese patients with type 2 diabetes, modest and sustained weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications (3–5). Small studies have demonstrated that in obese patients with type 2 diabetes more extreme dietary energy restriction with very low-calorie diets can reduce A1C to <6.5% (48 mmol/mol) and fasting glucose to <126 mg/dL (7.0 mmol/L) in the absence of pharmacological therapy or ongoing procedures (6,7). Weight loss–induced improvements in glycemia are most likely to occur early in the natural history of type 2 diabetes when obesity-associated insulin resistance has caused reversible β-cell dysfunction but insulin secretory capacity remains relatively preserved (5,8). Although the Action for Health in Diabetes (Look AHEAD) trial did not show that an intensive lifestyle intervention reduced cardiovascular events in overweight or obese adults with type 2 diabetes (9), it did show the feasibility of achieving and maintaining long-term weight loss in patients with type 2 diabetes.

Look AHEAD

In the Look AHEAD intensive lifestyle intervention group, mean weight loss was 4.7% (SE 0.2) at 8 years (10). Approximately 50% of intensive lifestyle intervention participants lost ≥5% and 27% lost ≥10% of their initial body weight at 8 years (10). Participants randomly assigned to the intensive lifestyle group achieved equivalent risk factor control but required fewer glucose-, blood pressure–, and lipid-lowering medications than those randomly assigned to standard care. Secondary analyses of the Look AHEAD trial and other large cardiovascular outcome studies document other benefits of weight loss in patients with type 2 diabetes, including improvements in mobility, physical and sexual functioning, and health-related quality of life (11). The goal of this section is to provide evidence-based recommendations for dietary, pharmacological, and surgical interventions for obesity management as treatments for hyperglycemia in type 2 diabetes.

Assessment

Recommendation

  • At each patient encounter, BMI should be calculated and documented in the medical record. B

At each routine patient encounter, BMI should be calculated from the height and weight. BMI should be classified to determine the presence of overweight or obesity, discussed with the patient, and documented in the patient record (Table 6.1). In Asian Americans, the BMI cutoff points to define overweight and obesity are lower: normal (<23 kg/m2), overweight (23.0–27.4 kg/m2), obese (27.5–37.4 kg/m2), and extremely obese (≥37.5 kg/m2) (12). Providers should advise overweight and obese patients that higher BMIs increase the risk of cardiovascular disease and all-cause mortality. Providers should assess each patient’s readiness to achieve weight loss and jointly determine weight loss goals and intervention strategies. Strategies include diet, physical activity, behavioral therapy, pharmacological therapy, and bariatric surgery (Table 6.1). The latter two strategies may be prescribed for carefully selected patients as adjuncts to diet, physical activity, and behavioral therapy.

View this table:
  • View inline
  • View popup
Table 6.1

Treatment for overweight and obesity in type 2 diabetes

Diet, Physical Activity, and Behavioral Therapy

Recommendations

  • Diet, physical activity, and behavioral therapy designed to achieve 5% weight loss should be prescribed for overweight and obese patients with type 2 diabetes ready to achieve weight loss. A

  • Such interventions should be high intensity (≥16 sessions in 6 months) and focus on diet, physical activity, and behavioral strategies to achieve a 500–750 kcal/day energy deficit. A

  • Diets that provide the same caloric restriction but differ in protein, carbohydrate, and fat content are equally effective in achieving weight loss. A

  • For patients who achieve short-term weight loss goals, long-term (≥1-year) comprehensive weight maintenance programs should be prescribed. Such programs should provide at least monthly contact and encourage ongoing monitoring of body weight (weekly or more frequently), continued consumption of a reduced calorie diet, and participation in high levels of physical activity (200–300 min/week). A

  • To achieve weight loss of >5%, short-term (3-month) high-intensity lifestyle interventions that use very low-calorie diets (≤800 kcal/day) and total meal replacements may be prescribed for carefully selected patients by trained practitioners in medical care settings with close medical monitoring. To maintain weight loss, such programs must incorporate long-term comprehensive weight maintenance counseling. B

Among overweight or obese patients with type 2 diabetes and inadequate glycemic, blood pressure and lipid control, and/or other obesity-related medical conditions, lifestyle changes that result in modest and sustained weight loss produce clinically meaningful reductions in blood glucose, A1C, and triglycerides (3–5). Greater weight loss produces even greater benefits, including reductions in blood pressure, improvements in LDL and HDL cholesterol, and reductions in the need for medications to control blood glucose, blood pressure, and lipids (9,10).

Lifestyle Interventions

Weight loss can be attained with lifestyle programs that achieve a 500–750 kcal/day energy deficit or provide approximately 1,200–1,500 kcal/day for women and 1,500–1,800 kcal/day for men, adjusted for the individual’s baseline body weight. Although benefits may be seen with as little as 5% weight loss, sustained weight loss of ≥7% is optimal.

These diets may differ in the types of foods they restrict (such as high-fat or high-carbohydrate foods) but are effective if they create the necessary energy deficit (13–16). The diet choice should be based on the patient’s health status and preferences.

Intensive behavioral lifestyle interventions should include ≥16 sessions in 6 months and focus on diet, physical activity, and behavioral strategies to achieve an ∼500–750 kcal/day energy deficit. Interventions should be provided by trained interventionists in either individual or group sessions (17).

Overweight and obese patients with type 2 diabetes who have lost weight during the 6-month intensive behavioral lifestyle intervention should be enrolled in long-term (≥1-year) comprehensive weight loss maintenance programs that provide at least monthly contact with a trained interventionist and focus on ongoing monitoring of body weight (weekly or more frequently), continued consumption of a reduced calorie diet, and participation in high levels of physical activity (200–300 min/week). Some commercial and proprietary weight loss programs have shown promising weight loss results (18).

When provided by trained practitioners in medical care settings with close medical monitoring, short-term (3-month) high-intensity lifestyle interventions that use very low-calorie diets (defined as ≤800 kcal/day) and total meal replacements may achieve greater short-term weight loss (10–15%) than intensive behavioral lifestyle interventions that typically achieve 5% weight loss. Weight regain following the cessation of high-intensity lifestyle interventions is greater than following intensive behavioral lifestyle interventions unless a long-term comprehensive weight loss maintenance program is provided (19,20).

Pharmacotherapy

Recommendations

  • When choosing glucose-lowering medications for overweight or obese patients with type 2 diabetes, consider their effect on weight. E

  • Whenever possible, minimize the medications for comorbid conditions that are associated with weight gain. E

  • Weight loss medications may be effective as adjuncts to diet, physical activity, and behavioral counseling for selected patients with type 2 diabetes and BMI ≥27 kg/m2. Potential benefits must be weighed against the potential risks of the medications. A

  • If a patient’s response to weight loss medications is <5% after 3 months or if there are any safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered. A

When considering pharmacological treatments for overweight or obese patients with type 2 diabetes, providers should first consider their choice of glucose-lowering medications. Whenever possible, medications should be chosen to promote weight loss or to be weight neutral. Agents associated with weight loss include metformin, α-glucosidase inhibitors, glucagon-like peptide 1 agonists, amylin mimetics, and sodium–glucose cotransporter 2 inhibitors. Dipeptidyl peptidase 4 inhibitors appear to be weight neutral. Unlike these agents, insulin secretagogues, thiazolidinediones, and insulin have often been associated with weight gain (see Section 7 “Approaches to Glycemic Treatment”).

Concomitant Medications

Providers should carefully review the patient’s concomitant medications and, whenever possible, minimize or provide alternatives for medications that promote weight gain. The latter include atypical antipsychotics (clozapine, olanzapine, risperidone, etc.) and antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors), glucocorticoids, oral contraceptives that contain progestins, anticonvulsants including gabapentin, and a number of antihistamines and anticholinergics.

Approved Medications

The U.S. Food and Drug Administration (FDA) has approved five weight loss medications (or combination medications) for long-term use by patients with BMI ≥27 kg/m2 with one or more obesity-associated comorbid conditions and by patients with BMI ≥30 kg/m2 who are motivated to lose weight (21–23). Medications approved for long-term weight loss and weight loss maintenance and their advantages and disadvantages are summarized in Table 6.2. The rationale for weight loss medications is to help patients to more consistently adhere to low-calorie diets and to reinforce lifestyle changes including physical activity. Providers should be knowledgeable about the product label and should balance the potential benefits of successful weight loss against the potential risks of the medication for each patient. All medications are FDA pregnancy category X. These medications are contraindicated in women who are or may become pregnant. Women in their reproductive years must be cautioned to use a reliable method of contraception.

View this table:
  • View inline
  • View popup
Table 6.2

Medications approved by the FDA for the long-term treatment of obesity

Assessing Efficacy and Safety

Efficacy and safety should be assessed at least monthly for the first 3 months of treatment. If a patient’s response is deemed insufficient (weight loss <5%) or if there are any safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered.

In general, pharmacological treatment of obesity has been limited by low adherence, modest efficacy, adverse effects, and weight regain after medication cessation (21).

Bariatric Surgery

Recommendations

  • Bariatric surgery may be considered for adults with BMI >35 kg/m2 and type 2 diabetes, especially if diabetes or associated comorbidities are difficult to control with lifestyle and pharmacological therapy. B

  • Patients with type 2 diabetes who have undergone bariatric surgery need lifelong lifestyle support and annual medical monitoring, at a minimum. B

  • Although small trials have shown a glycemic benefit of bariatric surgery in patients with type 2 diabetes and BMI 30–35 kg/m2, there is currently insufficient evidence to generally recommend surgery in patients with BMI ≤35 kg/m2. E

Bariatric and metabolic surgeries, either gastric banding or procedures that involve resecting, bypassing, or transposing sections of the stomach and small intestine, can be effective weight loss treatments for severe obesity when performed as part of a comprehensive weight management program with lifelong lifestyle support and medical monitoring. In one meta-analysis, gastric banding resulted in less weight loss than sleeve gastrectomy and Roux-en-Y gastric bypass (1-year excess weight loss ∼33% vs. ∼70%) (24). National guidelines support consideration of bariatric surgery for people with type 2 diabetes with BMI >35 kg/m2.

Advantages

Treatment with bariatric surgery has been shown to achieve near or complete normalization of glycemia 2 years following surgery in 72% of patients (compared with 16% in a matched control group treated with lifestyle and pharmacological interventions) (25). A study evaluated the effectiveness of surgical intervention (Roux-en-Y gastric bypass or sleeve gastrectomy) and medical therapy compared with medical therapy alone (quarterly visits, pharmacological therapy, self-monitoring of blood glucose, diabetes education, lifestyle counseling, and encouragement to participate in Weight Watchers) in achieving a target A1C ≤6% (42 mmol/mol) at 3 years among obese patients with uncontrolled type 2 diabetes (mean A1C 9.3% [78 mmol/mol]). This A1C target was achieved by 38% (P < 0.001) in the gastric bypass group, 24% (P = 0.01) in the sleeve gastrectomy group, and 5% in the group that received only medical therapy (26). Diabetes remission rates tend to be higher with procedures that bypass portions of the small intestine and lower with procedures that only restrict the stomach.

Younger age, shorter duration of type 2 diabetes, lower A1C, higher serum insulin levels, and nonuse of insulin have all been associated with higher remission rates after bariatric surgery (27).

Although bariatric surgery has been shown to improve the metabolic profiles of morbidly obese patients with type 1 diabetes, the role of bariatric surgery in such patients will require larger and longer studies (28).

Disadvantages

Bariatric surgery is costly and has associated risks. Morbidity and mortality rates directly related to the surgery have decreased considerably in recent years, with 30-day mortality rates now 0.2% for laparoscopic procedures, similar to those for laparoscopic cholecystectomy, and 2.1% for open procedures (29,30). Outcomes vary depending on the procedure and the experience of the surgeon and center. Longer-term concerns include dumping syndrome (nausea, colic, diarrhea), vitamin and mineral deficiencies, osteoporosis, and, rarely, severe hypoglycemia from insulin hypersecretion. More recent studies also suggest that patients who undergo bariatric surgery may be at increased risk for substance use, including drug and alcohol use and cigarette smoking (31). Cohort studies attempting to match surgical and nonsurgical subjects suggest that the procedure may reduce longer-term mortality (25).

In contrast, a propensity score–adjusted analysis of older, severely obese patients in Veterans Affairs Medical Centers found that bariatric surgery was not associated with decreased mortality compared with usual care (mean follow-up 6.7 years) (32). Retrospective analyses and modeling studies suggest that bariatric surgery may be cost-effective or even cost-saving for patients with type 2 diabetes, but the results are largely dependent on assumptions about the long-term effectiveness and safety of the procedures (33,34). Understanding the long-term benefits and risks of bariatric surgery in individuals with type 2 diabetes, especially those who are not severely obese, will require well-designed clinical trials, with optimal medical therapy as the comparator (35). Unfortunately, such studies may not be feasible (36).

Footnotes

  • Suggested citation: American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Sec. 6. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S47–S51

  • © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Tuomilehto J,
    2. Lindström J,
    3. Eriksson JG, et al.; Finnish Diabetes Prevention Study Group
    . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Knowler WC,
    2. Barrett-Connor E,
    3. Fowler SE, et al.; Diabetes Prevention Program Research Group
    . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. UK Prospective Diabetes Study 7
    . UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905–912
    OpenUrlCrossRefPubMedWeb of Science
    1. Goldstein DJ
    . Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397–415
    OpenUrlPubMedWeb of Science
  4. ↵
    1. Pastors JG,
    2. Warshaw H,
    3. Daly A,
    4. Franz M,
    5. Kulkarni K
    . The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002;25:608–613
    OpenUrlFREE Full Text
  5. ↵
    1. Lim EL,
    2. Hollingsworth KG,
    3. Aribisala BS,
    4. Chen MJ,
    5. Mathers JC,
    6. Taylor R
    . Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506–2514
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Jackness C,
    2. Karmally W,
    3. Febres G, et al
    . Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell function in type 2 diabetic patients. Diabetes 2013;62:3027–3032
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Rothberg AE,
    2. McEwen LN,
    3. Kraftson AT,
    4. Fowler CE,
    5. Herman WH
    . Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications 2014;28:506–510
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wing RR,
    2. Bolin P,
    3. Brancati FL, et al.; Look AHEAD Research Group
    . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–154
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Look AHEAD Research Group
    . Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 2014;22:5–13
    OpenUrlCrossRefPubMed
  10. ↵
    1. Wilding JPH
    . The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682–691
    OpenUrlCrossRefPubMed
  11. ↵
    1. WHO Expert Consultation
    . Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–163
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Sacks FM,
    2. Bray GA,
    3. Carey VJ, et al
    . Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859–873
    OpenUrlCrossRefPubMedWeb of Science
    1. de Souza RJ,
    2. Bray GA,
    3. Carey VJ, et al
    . Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr 2012;95:614–625
    OpenUrlAbstract/FREE Full Text
    1. Johnston BC,
    2. Kanters S,
    3. Bandayrel K, et al
    . Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923–933
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Jensen MD,
    2. Ryan DH,
    3. Apovian CM, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society
    . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63(25 Pt B):2985–3023
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Selph S, Dana T, Bougatsos C, Blazina I, Patel H, Chou R. Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation [Internet], 2015. Rockville, MD, Agency for Healthcare Research and Quality (Report No.: 13-05190-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews)
  15. ↵
    1. Gudzune KA,
    2. Doshi RS,
    3. Mehta AK, et al
    . Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med 2015;162:501–512
    OpenUrlCrossRefPubMed
  16. ↵
    1. Tsai AG,
    2. Wadden TA
    . The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283–1293
    OpenUrlCrossRefPubMed
  17. ↵
    1. Johansson K,
    2. Neovius M,
    3. Hemmingsson E
    . Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;99:14–23
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Yanovski SZ,
    2. Yanovski JA
    . Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74–86
    OpenUrlCrossRefPubMedWeb of Science
    1. Greenway FL,
    2. Fujioka K,
    3. Plodkowski RA, et al.; COR-I Study Group
    . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Pi-Sunyer X,
    2. Astrup A,
    3. Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group
    . A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22
    OpenUrlCrossRefPubMed
  20. ↵
    1. Chang S-H,
    2. Stoll CRT,
    3. Song J,
    4. Varela JE,
    5. Eagon CJ,
    6. Colditz GA
    . The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275–287
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Sjöström L,
    2. Peltonen M,
    3. Jacobson P, et al
    . Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297–2304
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Schauer PR,
    2. Bhatt DL,
    3. Kirwan JP, et al.; STAMPEDE Investigators
    . Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 2014;370:2002–2013
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Still CD,
    2. Wood GC,
    3. Benotti P, et al
    . Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2014;2:38–45
    OpenUrlCrossRefPubMed
  24. ↵
    1. Brethauer SA,
    2. Aminian A,
    3. Rosenthal RJ,
    4. Kirwan JP,
    5. Kashyap SR,
    6. Schauer PR
    . Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes. Diabetes Care 2014;37:e51–e52
    OpenUrlFREE Full Text
  25. ↵
    1. Buchwald H,
    2. Estok R,
    3. Fahrbach K,
    4. Banel D,
    5. Sledge I
    . Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007;142:621–632
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium
    . Peri-operative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361:445–454
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Conason A,
    2. Teixeira J,
    3. Hsu C-H,
    4. Puma L,
    5. Knafo D,
    6. Geliebter A
    . Substance use following bariatric weight loss surgery. JAMA Surg 2013;148:145–150
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Maciejewski ML,
    2. Livingston EH,
    3. Smith VA, et al
    . Survival among high-risk patients after bariatric surgery. JAMA 2011;305:2419–2426
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Hoerger TJ,
    2. Zhang P,
    3. Segel JE,
    4. Kahn HS,
    5. Barker LE,
    6. Couper S
    . Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care 2010;33:1933–1939
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Keating CL,
    2. Dixon JB,
    3. Moodie ML,
    4. Peeters A,
    5. Playfair J,
    6. O’Brien PE
    . Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care 2009;32:580–584
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Wolfe BM,
    2. Belle SH
    . Long-term risks and benefits of bariatric surgery: a research challenge. JAMA 2014;312:1792–1793
    OpenUrlCrossRefPubMed
  32. ↵
    1. Courcoulas AP,
    2. Goodpaster BH,
    3. Eagleton JK, et al
    . Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 2014;149:707–715
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 39 (Supplement 1)

In this Issue

January 2016, 39(Supplement 1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Complete Issue (PDF)
  • News Release
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
6. Obesity Management for the Treatment of Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
6. Obesity Management for the Treatment of Type 2 Diabetes
American Diabetes Association
Diabetes Care Jan 2016, 39 (Supplement 1) S47-S51; DOI: 10.2337/dc16-S009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

6. Obesity Management for the Treatment of Type 2 Diabetes
American Diabetes Association
Diabetes Care Jan 2016, 39 (Supplement 1) S47-S51; DOI: 10.2337/dc16-S009
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Look AHEAD
    • Assessment
    • Diet, Physical Activity, and Behavioral Therapy
    • Pharmacotherapy
    • Bariatric Surgery
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association
  • Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association
  • Diabetes and Hypertension: A Position Statement by the American Diabetes Association
Show more Position Statement

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.